Skip to Main Content

Paper Details

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â¿¿years of follow-up in the DAYBREAK open-label extension trial.
Multiple Sclerosis Journal
9
2022
MS, Ozanimod, Patients, T2, TEAEs, gadolinium, herpes zoster infections, macular edema, ozanimod, participants, patients, relapsing multiple sclerosis, sphingosine 1-phosphate, sphingosine 1-phosphate receptor 1 and 5
Author NameAffiliation
Bruce A C CreeWeill Institute for Neurosciences, University of California San Francisco
Krzysztof SelmajCenter for Neurology, University of Warmia and Mazury in Olsztyn
Giancarlo ComiVita-Salute San Raffaele University and Casa di Cura del Policlinico
Hans-Peter HartungHeinrich-Heine University, The University of Sydney, Medical University of Vienna, Palacky University Olomouc
Xavier MontalbanHospital Universitari Vall d'Hebron
  • 1 - 5

Datasets

Release 1.2